Models to predict positive prostate biopsies using the Tyrol screening study.

OBJECTIVE: To describe two predictive models that predict for prostate cancer on biopsy derived from a large screening population. There are no published predictive models that predict prostate cancer in a screened population. METHODS: The patients from the Tyrol screening study of known age, total...

Full description

Bibliographic Details
Main Authors: Sooriakumaran, P, John, M, Christos, P, Bektic, J, Bartsch, G, Leung, R, Herman, M, Scherr, D, Tewari, A
Format: Journal article
Language:English
Published: 2011
_version_ 1797054745260589056
author Sooriakumaran, P
John, M
Christos, P
Bektic, J
Bartsch, G
Leung, R
Herman, M
Scherr, D
Tewari, A
author_facet Sooriakumaran, P
John, M
Christos, P
Bektic, J
Bartsch, G
Leung, R
Herman, M
Scherr, D
Tewari, A
author_sort Sooriakumaran, P
collection OXFORD
description OBJECTIVE: To describe two predictive models that predict for prostate cancer on biopsy derived from a large screening population. There are no published predictive models that predict prostate cancer in a screened population. METHODS: The patients from the Tyrol screening study of known age, total prostate-specific antigen (PSA) level, digital rectal examination (DRE) findings, prostate volume, and percentage of free PSA, and who underwent an initial prostate biopsy from January 1992 to June 2004 were included (n = 2271). Multivariate logistic regression models were used to develop the biopsy positivity predictive models: nomogram 1, age, DRE, and total PSA; and nomogram 2, age, DRE, total PSA, and percentage of free PSA. The predictive accuracy of the models was assessed in terms of discrimination and calibration. External validation of the nomograms was performed using a urologically referred population of patients who underwent prostate biopsy (n = 599). RESULTS: Both nomograms were well-calibrated internally and externally and discriminated well between patients with positive and negative biopsy findings for both the European and U.S. cohorts (model 2 better than model 1). CONCLUSION: Our nomogram with age, total PSA, and DRE had good predictive ability to differentiate between screened patients with cancer on the initial prostate biopsy and those without. Adding the percentage of free PSA improves this predictive power further. These models might aid in clinical decision making regarding the need for biopsy in both European and U.S. populations.
first_indexed 2024-03-06T19:01:33Z
format Journal article
id oxford-uuid:13b3b4e1-60f2-466e-8b6e-0f322416a634
institution University of Oxford
language English
last_indexed 2024-03-06T19:01:33Z
publishDate 2011
record_format dspace
spelling oxford-uuid:13b3b4e1-60f2-466e-8b6e-0f322416a6342022-03-26T10:15:21ZModels to predict positive prostate biopsies using the Tyrol screening study.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:13b3b4e1-60f2-466e-8b6e-0f322416a634EnglishSymplectic Elements at Oxford2011Sooriakumaran, PJohn, MChristos, PBektic, JBartsch, GLeung, RHerman, MScherr, DTewari, A OBJECTIVE: To describe two predictive models that predict for prostate cancer on biopsy derived from a large screening population. There are no published predictive models that predict prostate cancer in a screened population. METHODS: The patients from the Tyrol screening study of known age, total prostate-specific antigen (PSA) level, digital rectal examination (DRE) findings, prostate volume, and percentage of free PSA, and who underwent an initial prostate biopsy from January 1992 to June 2004 were included (n = 2271). Multivariate logistic regression models were used to develop the biopsy positivity predictive models: nomogram 1, age, DRE, and total PSA; and nomogram 2, age, DRE, total PSA, and percentage of free PSA. The predictive accuracy of the models was assessed in terms of discrimination and calibration. External validation of the nomograms was performed using a urologically referred population of patients who underwent prostate biopsy (n = 599). RESULTS: Both nomograms were well-calibrated internally and externally and discriminated well between patients with positive and negative biopsy findings for both the European and U.S. cohorts (model 2 better than model 1). CONCLUSION: Our nomogram with age, total PSA, and DRE had good predictive ability to differentiate between screened patients with cancer on the initial prostate biopsy and those without. Adding the percentage of free PSA improves this predictive power further. These models might aid in clinical decision making regarding the need for biopsy in both European and U.S. populations.
spellingShingle Sooriakumaran, P
John, M
Christos, P
Bektic, J
Bartsch, G
Leung, R
Herman, M
Scherr, D
Tewari, A
Models to predict positive prostate biopsies using the Tyrol screening study.
title Models to predict positive prostate biopsies using the Tyrol screening study.
title_full Models to predict positive prostate biopsies using the Tyrol screening study.
title_fullStr Models to predict positive prostate biopsies using the Tyrol screening study.
title_full_unstemmed Models to predict positive prostate biopsies using the Tyrol screening study.
title_short Models to predict positive prostate biopsies using the Tyrol screening study.
title_sort models to predict positive prostate biopsies using the tyrol screening study
work_keys_str_mv AT sooriakumaranp modelstopredictpositiveprostatebiopsiesusingthetyrolscreeningstudy
AT johnm modelstopredictpositiveprostatebiopsiesusingthetyrolscreeningstudy
AT christosp modelstopredictpositiveprostatebiopsiesusingthetyrolscreeningstudy
AT bekticj modelstopredictpositiveprostatebiopsiesusingthetyrolscreeningstudy
AT bartschg modelstopredictpositiveprostatebiopsiesusingthetyrolscreeningstudy
AT leungr modelstopredictpositiveprostatebiopsiesusingthetyrolscreeningstudy
AT hermanm modelstopredictpositiveprostatebiopsiesusingthetyrolscreeningstudy
AT scherrd modelstopredictpositiveprostatebiopsiesusingthetyrolscreeningstudy
AT tewaria modelstopredictpositiveprostatebiopsiesusingthetyrolscreeningstudy